Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Microvascular endothelial cells display a large degree of heterogeneity in function depending on their location in the vascular tree. The existence of organ-specific, microvascular-bed-specific, and even intravascular variations in endothelial cell gene expression emphasizes their high cell-to-cell variability, which is furthermore extremely adaptable to altering conditions. The ability of microvascular endothelial cells to respond dynamically to pathology-related microenvironmental changes is particularly apparent in tumor-growth-associated angiogenesis. An understanding of how they behave, how their behavior varies between and within tumors, and how their behavior is related to responsiveness to drugs is critical for the development of effective anti-angiogenic treatment strategies. In this review, we introduce some general issues concerning organ-imprinted microvascular heterogeneity and highlight the importance of studying microvascular endothelial cell behavior in an in vivo context. This is followed by an overview of state-of-the-art knowledge regarding the nature of the variation in microenvironmental conditions in pre-clinical and clinical tumors and their consequences for tumor endothelial behavior. We provide recent insights into the in vivo molecular activation status of the endothelium and, finally, outline our current understanding of the way that anti-angiogenic drugs affect tumor endothelial cells in relation to their anti-tumor effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 2×
“…biological consequence of treatment with these inhibitors is unknown, but anti-angiogenic therapeutic strategies have been documented to result in hypoxia (Casanovas et al. 2005; Shaked et al. 2006), endothelial cell apoptosis (Laird et al. 2002), and normalization of the vasculature (Jain 2005).”
BackgroundVEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122 · cited 1×
“Moreover, the adaptor molecule Shb binds to phosphorylated Tyr1175, thereby activating phosphatidylinositol-3 kinase, which in turn activates the serine/threonine kinase AKT/protein kinase B pathway that mediates survival of the endothelial cells (Olsson et al. 2006).”
BackgroundTransplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640 · cited 1×
“Tumor endothelial heterogeneity and its consequences for anti-angiogenic therapy Angiogenesis is one of the main processes by means of which a tumor creates its own oxygen and nutrient supply and a route for systemic metastasis (Folkman 1971).”
BackgroundEvolving functions of endothelial cells in inflammation
Pober, J. S., & Sessa, W. C. (2007) · Nature Reviews Immunology · doi:10.1038/nri2171 · Cited by 2,022
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683 · cited 1×
“After several treatment cycles, no tumors recurred upon discontinuation of therapy, indicating that resistance to endostatin has not developed in these tumors (Boehm et al. 1997).”
BackgroundCasanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988 · cited 3×
“The studies by Bergers et al. (1999, 2003) unambiguously showed that the efficacy of angiogenesis inhibitors in the Rip-Tag2 model of multistage pancreatic carcinoma is tumor-growth stagedependent (Fig.”
BackgroundThe hypoxic response of tumors is dependent on their microenvironment
Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H.-P., Johnson, R. S., & Bergers, G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00194-6 · Cited by 408 · cited 3×
“growing astrocytomas, a 50% reduction in vessel density and a 30% decrease in tumor cell proliferation rate had been observed upon HIF-1α knock-out (Blouw et al. 2003).”
BackgroundInfluential
Cited by
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Integrated Single-Cell Atlas of Endothelial Cells of the Human Lung
Schupp, J. C., Adams, T. S., Cosme, C., Raredon, M. S. B., Yuan, Y., Omote, N., Poli, S., Chioccioli, M., Rose, K.-A., Manning, E. P., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052318 · Cited by 453
Understanding and exploiting nanoparticles' intimacy with the blood vessel and blood
Setyawati, M. I., Tay, C. Y., Docter, D., Stauber, R. H., & Leong, D. T. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00499c · Cited by 308
Contribution of Tumor Endothelial Cells in Cancer Progression
Hida, K., Maishi, N., Annan, D., & Hida, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051272 · Cited by 259
Metadata
- Authors
- Langenkamp, E., & Molema, G.
- Venue
- Cell and Tissue Research
- Published
- 2008-08-02
- Volume
- 335
- Issue
- 1
- Pages
- 205-222
- ISSN
- 0302-766X (ISSN-L)
- 1432-0878
- OpenAlex
- W2115668622
- Cited by
- 119
- References
- 8
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.